Antipsychotics: A Focus on Indications,
Monitoring, and Counseling
Clicking the "View this Article" button will open the issue as a resizable PDF. To take the test for
the issue, return to this Introduction page and click the "Take the Test" button. The Introduction
page will remain open after you open this issue.
You may need to re-size or close the issue in order
to see the Introduction page.
Antipsychotic therapy improves the lives of millions with severe and persistent mental illnesses like schizophrenia and bipolar disorder. In recent years, FDA-approved use has expanded to other indications including depression and autism spectrum disorder. There has also been an explosion of off-label (unapproved) use as varied as behavioral problems and anxiety.
Antipsychotics are classified as either first-generation (FGA, "typical", or conventional) or second generation (SGA or "atypical"). The SGAs are among the top 5 therapeutic classes undergoing significant growth in medication spending. Aripiprazole (Abilify®) and quetiapine (Seroquel®) rank among the top 10 prescription drugs in terms of sales.
The use of the older FGAs has declined, while the use of SGAs increased nearly 6-fold from 1995 to 2008 among both adults and children. Factors contributing to this increase include expanded indications beyond schizophrenia and better tolerability of SGAs. Aggressive marketing of SGAs, including direct-to-consumer advertising and illegal promotion, also may have contributed to the increase in use. The number of physician office visits at which antipsychotics were prescribed off-label almost doubled between 1995 and 2008. Concerns have been raised about off-label uses that lack sufficient evidence for efficacy and safety. This issue summarizes the current evidence for FDA-approved antipsychotic indications (see Table 1.) as well as nonapproved uses - with a focus on comparative safety and tolerability among the agents. The supplement to this issue addresses the history of antipsychotic use, important antipsychotic interactions, and the SGA clozapine. Additional CE credit is available for the supplement.
Understanding the benefits and risks of antipsychotic use, especially in vulnerable patient populations such as children and elders, is critical for providing quality healthcare. Community practitioners can take an active role in working with patients and caregivers to ensure that antipsychotics are used for appropriate indications, and to provide them with recommended monitoring and education to improve safety.
Publication Date: 07/18/2013
Expiration Date: 07/18/2016
CE Credit: 1.5 (0.15 CEU)
Type of Activity: Knowledge-based
This program was developed by The Rx Consultant and published by Continuing Education Network, Inc.
The Rx Consultant accepts no advertising or financial support from the pharmaceutical industry and
is funded solely by the purchase of programs. The Rx Consultant is dedicated to providing unbiased,
balanced information to health care practitioners.
Programs developed by The Rx Consultant are written by health care providers with expertise in the topic
area, peer-reviewed, extensively edited, and fact-checked. This development process was created to insure
that every program presents information that is current, accurate, relevant to "real world" health care
providers, and written in an easy reading, "plain English" style.
Julie Dopheide, PharmD, BCPP, Tracy Farnen, PharmD, and Pamela Mausner, MD
Dr. Dopheide, Dr. Farnen and Dr. Mausner report no financial or personal relationship with any commercial interest producing, marketing, reselling, or distributing a product or service that appears in this issue.
This accredited program is targeted to pharmacists and nurses.
Goals & Objectives
At the conclusion of this program, participants will be able to:
- For commonly prescribed SGAs, state the FDA-approved indications and age ranges. Identify 2 off-label uses of antipsychotics for which there is at least limited evidence for efficacy.
- Discuss extrapyramidal symptoms (EPS), metabolic effects, QT prolongation, and hyperprolactinemia associated with antipsychotics; list the agents most likely to cause them.
- Provide recommendations to patients, families, and healthcare providers for managing antipsychotic adverse effects; include important monitoring parameters.
- Discuss the relative effectiveness of the most commonly used SGAs in treating schizophrenia.
The Rx Consultant is a publication of Continuing Education Network, Inc.
Continuing Education Network, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education as a
provider of continuing pharmacy education.
Continuing Education Network is approved by the California Board of Registered Nursing, Provider Number CEP 13118. Programs approved by CA BRN are accepted by most State Boards of Nursing.
ACPE Universal Activity Number: 0428-0000-13-009-H01-P
Exam & Credit Statement Procedures
Upon successful completion of this program and the post test (70%), 1.5 hours of continuing education credit will be awarded. To receive credit and your exam score, please complete the exam questions and
Editorial and Review Board
Chief Editor and CE Administrator
Terry M. Baker, PharmD
Tracy Farnen, PharmD
James Chan, PharmD, PhD
Pharmacy Quality and Outcomes Coordinator
Associate Clinical Professor
School of Pharmacy
University of California San Francisco
San Francisco, CA
Richard Ron Finley, B.S. Pharm.,R.Ph.
Clinical Pharmacist (volunteer faculty)
University of California, San Francisco (UCSF) Memory and Aging Center
Lecturer (Emeritus) UCSF, Department of Clinical Pharmacy
Health Sciences Clinical Professor, UCSF School of Pharmacy
San Francisco, CA
Ray Dolby Brain Health Center, Sutter Health/CPMC
San Francisco, CA
Consult Pharmacist Aging and Adult Health Services
San Francisco Health Department
San Francisco, CA
Julio R. Lopez, PharmD, FCSHP
Chief of Pharmacy Service
VA Northern California Health Care System
Adjunct Clinical Professor
College of Pharmacy
Assistant Clinical Professor
School of Pharmacy
University of California, San Francisco
San Francisco, CA Adjunct Professor
Thomas J. Long School of Pharmacy
University of the Pacific
Visiting Associate Professor and Lecturer
Samuel Merritt University
Pamela Mausner, MD
Helen Berlie, Pharm.D. CDE, BCACP
Clinical Assistant Professor, Pharmacy Practice
Wayne State University
Ambulatory Care Specialist - Diabetes
Health Centers Detroit Medical Group
Senior Editorial Advisor
Gerard Hatheway, PharmD, PhD
Belinda M. Danielson, RPh
Christopher M. DeSoto, PharmD
Angie S. Graham, PharmD
Cynthia Chan Huang, PharmD, MBA
Fred Plageman, PharmD
Editorial Advisor and Clinical Practice Consultant for Nurse Practitioners
Meuleman, RN, C, MS
About the Rx Consultant
The Rx Consultant is a monthly publication dedicated to providing health care professionals with the information they need to
educate patients about drugs and manage drug therapy. The reader is responsible for confirming
the information presented here and interpreting it in relation to each patient's specific situation before utilizing the information.
Any hardware that supports Microsoft Windows, Apple Mac OS, iOS, or Android, and meets the software requirements.
Browser that supports TLS 1.1 + and PDF files.
This includes Microsoft Internet Explorer 11, Google Chrome 38, Google Android OS 5.0 Browser, Apple Safari (version 7 for desktop, 5 for mobile), Mozilla Firefox 27, newer versions of these browsers, as well as some earlier versions that may require additional configuration.
Adobe Acrobat Reader is recommended, and is required for some browsers.
Note: TLS 1.1 and 1.2 support is required for browser security. Click here for TLS browser support details.
Required. Broadband recommended. (T1, DSL, Cable, G4 or higher.)